Clinical trial of Cerebroprotein Hydrolysate for Injection completes

Hard to Treat Diseases (the "Company") (HTDS.PK) announced today, that its China based subsidiary Mellow Hope, has just finished (August 2009) the clinical trial of Cerebroprotein Hydrolysate for Injection (Brand name: NUTRIPROTEIN) in India.

This biological product is a unique nutriment for the brain. It helps CNS in multiple ways, regulating and improving nerve cell metabolism, promoting synapse generation, inducing nerve cell differentiation, protecting nerve cells against damages by ischemia and neurotoxins etc.

This clinical trial is a multicentre one, authorized by Mellow Hope and sponsored by our partner Lupin Limited which is one of the top 3 pharmaceutical companies in India. http://www.lupinworld.com. The aim of this trial is to evaluate the efficacy and safety of this product in the management of subjects with Dementia in an open labeled, prospective, phase-III clinical trial. Through this clinical trial, this product has been approved with very good efficacy and safety.

In other company news, the revised business plan under consideration as per the issuer's news announcement of yesterday September 3 2009 includes an anti-aging and cancer treatment project. More information about cancer treatment project will be shortly available with Slavica Bio Chem (Slavica) on the updated website www.Slavicabiochem.com. Slavica is a second operating subsidiary of HTDS in Serbia, Europe. The aforementioned Mellow Hope and Lupin World clinical trial and cooperation is in addition to research work of Slavica.

Mr. Terry Yuan CEO of HTDS said (sic) "With the completion of this clinical trial, we are expected to receive the registration approval for NUTRIPROTEIN within three months in India. As soon as we get the approval, we will launch this product in the local market. Without any competitors in India, we will win a large market shares."

The issuer intends to provide further updates to its shareholders from both Mellow Hope in China and Slavica Bio Chem in Serbia operations on a frequent basis including certain developments on the anti-aging and cancer treatment project which the issuer is hopeful will have a significant and positive impact on its share price and add value to its shareholders.